argenx NV ADR (ARGX)vsInhibrx Biosciences, Inc. (INBX)
ARGX
argenx NV ADR
$888.65
+5.82%
HEALTHCARE · Cap: $56.45B
INBX
Inhibrx Biosciences, Inc.
$95.31
-4.65%
HEALTHCARE · Cap: $1.40B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 364705% more annual revenue ($4.74B vs $1.30M). ARGX leads profitability with a 31.4% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
INBX
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.1%
Fair Value
$2204.33
Current Price
$888.65
$1315.68 discount
Margin of Safety
-64.3%
Fair Value
$49.90
Current Price
$95.31
$45.41 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 187.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : INBX
The strongest argument for INBX centers on Debt/Equity.
Bear Case : ARGX
The primary concerns for ARGX are Piotroski F-Score, P/E Ratio, Price/Book. A P/E of 40.2x leaves little room for execution misses.
Bear Case : INBX
The primary concerns for INBX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ARGX profiles as a growth stock while INBX is a value play — different risk/reward profiles.
INBX carries more volatility with a beta of 3.32 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 20/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Inhibrx Biosciences, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?